Product Code: RP-ID-10070789 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10070789
Market Overview:
Myasthenia Gravis (MG) Disease Market Segmentation by Treatment [(Medication (Cholinesterase, Inhibitors, Corticosteroids, and Immunosuppressant), Surgery, Therapy (Thymectomy, Monoclonal Antibody, Plasmapheresis, and Intravenous immunoglobulin), and Others)]; and by End-Users (Hospitals, Clinics, Retail Pharmacies, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Global Myasthenia Gravis (MG) Disease Market Highlights Over 2022 - 2031
The global myasthenia gravis (MG) disease market catered to the revenue figure of approximately USD 1.5 billion in the year 2021 and is estimated to grow at a CAGR of ~10% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the growing cases of neuromuscular disorders, rising prevalence of the myasthenia gravis, and advancement in the biotechnological sector. Even though the disease is not specific to any particular age group, its prevalence is most commonly visible in young women aged between 20 to 30 and men aged 50 and above. According to Myasthenia Gravis Foundation of America, an estimated 14 to 20 per 100,000 population, are suffering from MG, in the United States.
-Disease-Market.jpg)
CLICK TO DOWNLOAD A SAMPLE REPORT
Myasthenia gravis (MG) is a long-term neuromuscular disease leading to skeletal muscle weakness. In the condition of MG, the immune system disrupts the transmission of nerve impulses to muscles by producing antibodies. Although the cure for this condition is still under research, awareness about the treatment at an early stage can help reduce and improve muscle weakness. The high prevalence of myasthenia gravis along with high investment in research & development of drugs is a key factor contributing towards the growth of the global myasthenia gravis disease market.
The global myasthenia gravis (MG) disease market is segmented based on treatment, and end-users. The treatment segment is further divided into medication, surgery, therapy, and others. Amongst these segments, the therapy segment is expected to show notable growth in the upcoming years. Further, this segment is divided into thymectomy, monoclonal antibody, plasmapheresis, and intravenous immunoglobulin. Out of these, the thymectomy segment is expected to hold the largest market value by growing at a significant CAGR during the forecast period. The procedure of thymectomy includes the removal of thymus gland in order to minimize the symptoms by rebalancing the immune system. The growth of the segment can be attributed to the effective and painless outcome of the treatment.
Global Myasthenia Gravis (MG) Disease Market Regional Synopsis
Regionally, the global myasthenia gravis (MG) disease market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Among these regions, the market in North America witnessed modest growth in the year 2021. This growth can be attributed to the advanced facilities available in the clinical setups in this region. As per the report given by the Myasthenia Gravis Foundation of America, the prevalence of MG disease is estimated around 36,000 to 60,000 cases in the United States. Alternatively, the market in the Asia Pacific region is expected to grow with a higher CAGR over the forecast period. The growth of the market can be associated on the back of increasing initiatives by government and private organizations for generating effective treatment along with increasing awareness about neuromuscular disorders and vast improvements in the healthcare sector in this region.
Market Segmentation
Our in-depth analysis of the global myasthenia gravis (MG) disease market includes the following segments:
By Treatment
- Medication
-
Cholinesterase
-
Inhibitors
-
Corticosteroids
-
Immunosuppressant
-
- Surgery
- Therapy
-
Thymectomy
-
Monoclonal Antibody
-
Plasmapheresis
-
Intravenous immunoglobulin
-
- Others
By End Users
-
Hospitals
-
Clinics
-
Retail Pharmacies
-
Others
Growth Drivers and Challenges Impacting the Growth of the Myasthenia Gravis (MG) Disease Market
Growth Drivers
-
Increasing cases of neuromuscular disorder
-
Increasing clinical facilities
-
Growing awareness about the treatment
Challenges
-
High cost of treatment
-
Lack of awareness about symptoms of MG
Key Companies Dominating the Myasthenia Gravis (MG) Disease Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global myasthenia gravis (MG) disease market that are included in our report are Alexion Pharmaceuticals, Inc., AbbVie Inc., argenx SE, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, Bausch Health Companies Inc., Avadel, Grifols, S.A., Pfizer Inc., and others.
Latest Developments in the Global Myasthenia Gravis (MG) Disease Market:
-
17 December 2021: A global immunology company, argenx which was working on the creation of treatment for generalized myasthenia gravis called “VYVGART”, announced that the U.S Food and Drug Administration (FDA) approved VYVGART’s use for the treatment of generalized myasthenia gravis (gMG) in adult patients.
-
12 December 2020: Alexion Pharmaceuticals, Inc, announced the agreement of acquisition in which the company named AstraZeneca will take over Alexion Pharmaceuticals, Inc, providing each Alexion shareholder with cash of USD 60.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirements helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Alexion Pharmaceuticals Inc.
- AbbVie Inc.
- argenx SE
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bausch Health Companies Inc.
- Avadel
- Grifols
- S.A.
- Pfizer Inc.
Related Reports
Proof of Quality & Reliability
